nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Pustule—Erlotinib—pancreatic cancer	0.074	0.0834	CcSEcCtD
Methyl aminolevulinate—Macular oedema—Tamoxifen—pancreatic cancer	0.0414	0.0467	CcSEcCtD
Methyl aminolevulinate—Skin infection—Sunitinib—pancreatic cancer	0.0287	0.0324	CcSEcCtD
Methyl aminolevulinate—Scab—Fluorouracil—pancreatic cancer	0.0215	0.0242	CcSEcCtD
Methyl aminolevulinate—Allergic contact dermatitis—Fluorouracil—pancreatic cancer	0.0196	0.0221	CcSEcCtD
Methyl aminolevulinate—Eyelid oedema—Sunitinib—pancreatic cancer	0.0172	0.0194	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Erlotinib—pancreatic cancer	0.0168	0.019	CcSEcCtD
Methyl aminolevulinate—Keratitis—Erlotinib—pancreatic cancer	0.0154	0.0174	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Sunitinib—pancreatic cancer	0.0146	0.0164	CcSEcCtD
Methyl aminolevulinate—Blister—Tamoxifen—pancreatic cancer	0.014	0.0158	CcSEcCtD
Methyl aminolevulinate—Blister—Erlotinib—pancreatic cancer	0.0139	0.0157	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Erlotinib—pancreatic cancer	0.0126	0.0142	CcSEcCtD
Methyl aminolevulinate—Blister—Sunitinib—pancreatic cancer	0.012	0.0136	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Fluorouracil—pancreatic cancer	0.0115	0.013	CcSEcCtD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—pancreatic cancer	0.00999	0.0882	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Tamoxifen—pancreatic cancer	0.00966	0.0109	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Erlotinib—pancreatic cancer	0.00956	0.0108	CcSEcCtD
Methyl aminolevulinate—Blister—Fluorouracil—pancreatic cancer	0.00949	0.0107	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Epirubicin—pancreatic cancer	0.00932	0.0105	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Doxorubicin—pancreatic cancer	0.00862	0.00972	CcSEcCtD
Methyl aminolevulinate—Stinging—Fluorouracil—pancreatic cancer	0.00844	0.00952	CcSEcCtD
Methyl aminolevulinate—Swelling—Tamoxifen—pancreatic cancer	0.00833	0.00939	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Docetaxel—pancreatic cancer	0.0083	0.00936	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Sunitinib—pancreatic cancer	0.00827	0.00933	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Fluorouracil—pancreatic cancer	0.00801	0.00903	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Tamoxifen—pancreatic cancer	0.00769	0.00867	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Erlotinib—pancreatic cancer	0.0076	0.00857	CcSEcCtD
Methyl aminolevulinate—Ulcer—Irinotecan—pancreatic cancer	0.00755	0.00851	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—CD44—pancreatic cancer	0.00752	0.0664	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CB—pancreatic cancer	0.00738	0.0652	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Gemcitabine—pancreatic cancer	0.00735	0.00829	CcSEcCtD
Methyl aminolevulinate—Ulcer—Fluorouracil—pancreatic cancer	0.00723	0.00815	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Docetaxel—pancreatic cancer	0.0071	0.00801	CcSEcCtD
Methyl aminolevulinate—Eczema—Sunitinib—pancreatic cancer	0.007	0.00789	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Fluorouracil—pancreatic cancer	0.00676	0.00762	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Gemcitabine—pancreatic cancer	0.00664	0.00749	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Sunitinib—pancreatic cancer	0.00658	0.00742	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA5—pancreatic cancer	0.00649	0.0573	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Sunitinib—pancreatic cancer	0.00607	0.00685	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Docetaxel—pancreatic cancer	0.00578	0.00652	CcSEcCtD
Methyl aminolevulinate—Swelling—Fluorouracil—pancreatic cancer	0.00563	0.00634	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Epirubicin—pancreatic cancer	0.0056	0.00631	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Gemcitabine—pancreatic cancer	0.00528	0.00596	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Fluorouracil—pancreatic cancer	0.00519	0.00586	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Doxorubicin—pancreatic cancer	0.00518	0.00584	CcSEcCtD
Methyl aminolevulinate—Keratitis—Epirubicin—pancreatic cancer	0.00513	0.00579	CcSEcCtD
Methyl aminolevulinate—Face oedema—Gemcitabine—pancreatic cancer	0.00487	0.0055	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Epirubicin—pancreatic cancer	0.00479	0.0054	CcSEcCtD
Methyl aminolevulinate—Keratitis—Doxorubicin—pancreatic cancer	0.00475	0.00536	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Docetaxel—pancreatic cancer	0.00471	0.00531	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Erlotinib—pancreatic cancer	0.0047	0.0053	CcSEcCtD
Methyl aminolevulinate—Blister—Epirubicin—pancreatic cancer	0.00462	0.00521	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CA—pancreatic cancer	0.0045	0.0397	CbGpPWpGaD
Methyl aminolevulinate—Burning sensation—Doxorubicin—pancreatic cancer	0.00443	0.005	CcSEcCtD
Methyl aminolevulinate—Erythema—Tamoxifen—pancreatic cancer	0.00442	0.00499	CcSEcCtD
Methyl aminolevulinate—Erythema—Erlotinib—pancreatic cancer	0.00438	0.00494	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA5—pancreatic cancer	0.00433	0.0383	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Epirubicin—pancreatic cancer	0.00428	0.00482	CcSEcCtD
Methyl aminolevulinate—Blister—Doxorubicin—pancreatic cancer	0.00427	0.00482	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Epirubicin—pancreatic cancer	0.00417	0.00471	CcSEcCtD
Methyl aminolevulinate—Stinging—Epirubicin—pancreatic cancer	0.00411	0.00463	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Sunitinib—pancreatic cancer	0.00407	0.00459	CcSEcCtD
Methyl aminolevulinate—Swelling—Docetaxel—pancreatic cancer	0.00406	0.00458	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Doxorubicin—pancreatic cancer	0.00396	0.00446	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Fluorouracil—pancreatic cancer	0.00392	0.00442	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Doxorubicin—pancreatic cancer	0.00386	0.00435	CcSEcCtD
Methyl aminolevulinate—Stinging—Doxorubicin—pancreatic cancer	0.0038	0.00429	CcSEcCtD
Methyl aminolevulinate—Erythema—Sunitinib—pancreatic cancer	0.00379	0.00427	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Docetaxel—pancreatic cancer	0.00375	0.00423	CcSEcCtD
Methyl aminolevulinate—Discomfort—Tamoxifen—pancreatic cancer	0.00372	0.0042	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—CD44—pancreatic cancer	0.00367	0.0324	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Tamoxifen—pancreatic cancer	0.00361	0.00407	CcSEcCtD
Methyl aminolevulinate—Infection—Tamoxifen—pancreatic cancer	0.00359	0.00404	CcSEcCtD
Methyl aminolevulinate—Oedema—Erlotinib—pancreatic cancer	0.00357	0.00403	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA1—pancreatic cancer	0.00356	0.0314	CbGpPWpGaD
Methyl aminolevulinate—Infection—Erlotinib—pancreatic cancer	0.00355	0.004	CcSEcCtD
Methyl aminolevulinate—Ulcer—Epirubicin—pancreatic cancer	0.00352	0.00397	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA2—pancreatic cancer	0.00331	0.0292	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis contact—Epirubicin—pancreatic cancer	0.00329	0.00371	CcSEcCtD
Methyl aminolevulinate—Ulcer—Doxorubicin—pancreatic cancer	0.00326	0.00367	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Tamoxifen—pancreatic cancer	0.00324	0.00366	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RAP1GAP—pancreatic cancer	0.00318	0.0281	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Epirubicin—pancreatic cancer	0.00318	0.00358	CcSEcCtD
Methyl aminolevulinate—Fatigue—Tamoxifen—pancreatic cancer	0.00311	0.00351	CcSEcCtD
Methyl aminolevulinate—Oedema—Sunitinib—pancreatic cancer	0.00309	0.00349	CcSEcCtD
Methyl aminolevulinate—Pain—Tamoxifen—pancreatic cancer	0.00309	0.00348	CcSEcCtD
Methyl aminolevulinate—Fatigue—Erlotinib—pancreatic cancer	0.00308	0.00347	CcSEcCtD
Methyl aminolevulinate—Infection—Sunitinib—pancreatic cancer	0.00307	0.00346	CcSEcCtD
Methyl aminolevulinate—Pain—Erlotinib—pancreatic cancer	0.00305	0.00344	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Doxorubicin—pancreatic cancer	0.00304	0.00343	CcSEcCtD
Methyl aminolevulinate—Erythema—Gemcitabine—pancreatic cancer	0.00304	0.00343	CcSEcCtD
Methyl aminolevulinate—Erythema—Fluorouracil—pancreatic cancer	0.00299	0.00337	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Doxorubicin—pancreatic cancer	0.00294	0.00332	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CB—pancreatic cancer	0.00288	0.0255	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Tamoxifen—pancreatic cancer	0.00287	0.00323	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Sunitinib—pancreatic cancer	0.00278	0.00313	CcSEcCtD
Methyl aminolevulinate—Eczema—Epirubicin—pancreatic cancer	0.00269	0.00303	CcSEcCtD
Methyl aminolevulinate—Eye pain—Epirubicin—pancreatic cancer	0.00268	0.00302	CcSEcCtD
Methyl aminolevulinate—Fatigue—Sunitinib—pancreatic cancer	0.00267	0.00301	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00266	0.003	CcSEcCtD
Methyl aminolevulinate—Pain—Sunitinib—pancreatic cancer	0.00264	0.00298	CcSEcCtD
Methyl aminolevulinate—Discomfort—Irinotecan—pancreatic cancer	0.00263	0.00296	CcSEcCtD
Methyl aminolevulinate—Asthenia—Tamoxifen—pancreatic cancer	0.00259	0.00292	CcSEcCtD
Methyl aminolevulinate—Asthenia—Erlotinib—pancreatic cancer	0.00256	0.00289	CcSEcCtD
Methyl aminolevulinate—Discomfort—Gemcitabine—pancreatic cancer	0.00256	0.00288	CcSEcCtD
Methyl aminolevulinate—Pruritus—Tamoxifen—pancreatic cancer	0.00255	0.00288	CcSEcCtD
Methyl aminolevulinate—Oedema—Irinotecan—pancreatic cancer	0.00255	0.00287	CcSEcCtD
Methyl aminolevulinate—Infection—Irinotecan—pancreatic cancer	0.00253	0.00285	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Epirubicin—pancreatic cancer	0.00253	0.00285	CcSEcCtD
Methyl aminolevulinate—Pruritus—Erlotinib—pancreatic cancer	0.00253	0.00285	CcSEcCtD
Methyl aminolevulinate—Discomfort—Fluorouracil—pancreatic cancer	0.00251	0.00284	CcSEcCtD
Methyl aminolevulinate—Eczema—Doxorubicin—pancreatic cancer	0.00249	0.00281	CcSEcCtD
Methyl aminolevulinate—Oedema—Gemcitabine—pancreatic cancer	0.00248	0.0028	CcSEcCtD
Methyl aminolevulinate—Eye pain—Doxorubicin—pancreatic cancer	0.00248	0.00279	CcSEcCtD
Methyl aminolevulinate—Infection—Gemcitabine—pancreatic cancer	0.00246	0.00278	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—CD44—pancreatic cancer	0.00245	0.0216	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Fluorouracil—pancreatic cancer	0.00244	0.00275	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA5—pancreatic cancer	0.00243	0.0215	CbGpPWpGaD
Methyl aminolevulinate—Infection—Fluorouracil—pancreatic cancer	0.00242	0.00273	CcSEcCtD
Methyl aminolevulinate—Dizziness—Tamoxifen—pancreatic cancer	0.00239	0.00269	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA1—pancreatic cancer	0.00237	0.021	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Erlotinib—pancreatic cancer	0.00236	0.00266	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—DTX4—pancreatic cancer	0.00236	0.0208	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Doxorubicin—pancreatic cancer	0.00234	0.00264	CcSEcCtD
Methyl aminolevulinate—Face oedema—Epirubicin—pancreatic cancer	0.00233	0.00263	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Docetaxel—pancreatic cancer	0.00232	0.00261	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—pancreatic cancer	0.00231	0.0204	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Irinotecan—pancreatic cancer	0.00229	0.00258	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Sunitinib—pancreatic cancer	0.00228	0.00257	CcSEcCtD
Methyl aminolevulinate—Rash—Tamoxifen—pancreatic cancer	0.00228	0.00257	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Tamoxifen—pancreatic cancer	0.00227	0.00256	CcSEcCtD
Methyl aminolevulinate—Headache—Tamoxifen—pancreatic cancer	0.00226	0.00255	CcSEcCtD
Methyl aminolevulinate—Rash—Erlotinib—pancreatic cancer	0.00225	0.00254	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Erlotinib—pancreatic cancer	0.00225	0.00254	CcSEcCtD
Methyl aminolevulinate—Headache—Erlotinib—pancreatic cancer	0.00224	0.00252	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Gemcitabine—pancreatic cancer	0.00223	0.00251	CcSEcCtD
Methyl aminolevulinate—Asthenia—Sunitinib—pancreatic cancer	0.00222	0.0025	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA2—pancreatic cancer	0.00221	0.0195	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PPP2R5B—pancreatic cancer	0.0022	0.0195	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Irinotecan—pancreatic cancer	0.0022	0.00248	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Fluorouracil—pancreatic cancer	0.00219	0.00247	CcSEcCtD
Methyl aminolevulinate—Pruritus—Sunitinib—pancreatic cancer	0.00219	0.00247	CcSEcCtD
Methyl aminolevulinate—Pain—Irinotecan—pancreatic cancer	0.00218	0.00246	CcSEcCtD
Methyl aminolevulinate—Face oedema—Doxorubicin—pancreatic cancer	0.00216	0.00243	CcSEcCtD
Methyl aminolevulinate—Erythema—Docetaxel—pancreatic cancer	0.00216	0.00243	CcSEcCtD
Methyl aminolevulinate—Nausea—Tamoxifen—pancreatic cancer	0.00214	0.00242	CcSEcCtD
Methyl aminolevulinate—Fatigue—Gemcitabine—pancreatic cancer	0.00214	0.00241	CcSEcCtD
Methyl aminolevulinate—Pain—Gemcitabine—pancreatic cancer	0.00212	0.00239	CcSEcCtD
Methyl aminolevulinate—Nausea—Erlotinib—pancreatic cancer	0.00212	0.00239	CcSEcCtD
Methyl aminolevulinate—Pain—Fluorouracil—pancreatic cancer	0.00209	0.00235	CcSEcCtD
Methyl aminolevulinate—Dizziness—Sunitinib—pancreatic cancer	0.00204	0.00231	CcSEcCtD
Methyl aminolevulinate—Rash—Sunitinib—pancreatic cancer	0.00195	0.0022	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Sunitinib—pancreatic cancer	0.00195	0.0022	CcSEcCtD
Methyl aminolevulinate—Urticaria—Fluorouracil—pancreatic cancer	0.00194	0.00219	CcSEcCtD
Methyl aminolevulinate—Headache—Sunitinib—pancreatic cancer	0.00194	0.00218	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—RAP1GAP—pancreatic cancer	0.00193	0.017	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00191	0.00215	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Irinotecan—pancreatic cancer	0.00188	0.00212	CcSEcCtD
Methyl aminolevulinate—Nausea—Sunitinib—pancreatic cancer	0.00184	0.00207	CcSEcCtD
Methyl aminolevulinate—Asthenia—Irinotecan—pancreatic cancer	0.00183	0.00206	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Fluorouracil—pancreatic cancer	0.0018	0.00203	CcSEcCtD
Methyl aminolevulinate—Asthenia—Gemcitabine—pancreatic cancer	0.00178	0.00201	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.00176	0.00199	CcSEcCtD
Methyl aminolevulinate—Oedema—Docetaxel—pancreatic cancer	0.00176	0.00199	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CA—pancreatic cancer	0.00176	0.0155	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Gemcitabine—pancreatic cancer	0.00176	0.00198	CcSEcCtD
Methyl aminolevulinate—Infection—Docetaxel—pancreatic cancer	0.00175	0.00197	CcSEcCtD
Methyl aminolevulinate—Pruritus—Fluorouracil—pancreatic cancer	0.00173	0.00195	CcSEcCtD
Methyl aminolevulinate—Dizziness—Irinotecan—pancreatic cancer	0.00168	0.0019	CcSEcCtD
Methyl aminolevulinate—Dizziness—Fluorouracil—pancreatic cancer	0.00161	0.00182	CcSEcCtD
Methyl aminolevulinate—Rash—Irinotecan—pancreatic cancer	0.00161	0.00181	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Irinotecan—pancreatic cancer	0.0016	0.00181	CcSEcCtD
Methyl aminolevulinate—Headache—Irinotecan—pancreatic cancer	0.0016	0.0018	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Docetaxel—pancreatic cancer	0.00158	0.00178	CcSEcCtD
Methyl aminolevulinate—Rash—Gemcitabine—pancreatic cancer	0.00156	0.00176	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Gemcitabine—pancreatic cancer	0.00156	0.00176	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Epirubicin—pancreatic cancer	0.00156	0.00176	CcSEcCtD
Methyl aminolevulinate—Headache—Gemcitabine—pancreatic cancer	0.00155	0.00175	CcSEcCtD
Methyl aminolevulinate—Rash—Fluorouracil—pancreatic cancer	0.00154	0.00173	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Fluorouracil—pancreatic cancer	0.00154	0.00173	CcSEcCtD
Methyl aminolevulinate—Headache—Fluorouracil—pancreatic cancer	0.00153	0.00172	CcSEcCtD
Methyl aminolevulinate—Fatigue—Docetaxel—pancreatic cancer	0.00152	0.00171	CcSEcCtD
Methyl aminolevulinate—Nausea—Irinotecan—pancreatic cancer	0.00151	0.00171	CcSEcCtD
Methyl aminolevulinate—Pain—Docetaxel—pancreatic cancer	0.00151	0.0017	CcSEcCtD
Methyl aminolevulinate—Nausea—Gemcitabine—pancreatic cancer	0.00147	0.00166	CcSEcCtD
Methyl aminolevulinate—Erythema—Epirubicin—pancreatic cancer	0.00146	0.00164	CcSEcCtD
Methyl aminolevulinate—Nausea—Fluorouracil—pancreatic cancer	0.00145	0.00163	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Doxorubicin—pancreatic cancer	0.00145	0.00163	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA5—pancreatic cancer	0.00142	0.0125	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—DTX4—pancreatic cancer	0.00137	0.0121	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Doxorubicin—pancreatic cancer	0.00135	0.00152	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PPP2R5B—pancreatic cancer	0.00134	0.0118	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA1—pancreatic cancer	0.00133	0.0118	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Docetaxel—pancreatic cancer	0.0013	0.00146	CcSEcCtD
Methyl aminolevulinate—Asthenia—Docetaxel—pancreatic cancer	0.00126	0.00142	CcSEcCtD
Methyl aminolevulinate—Pruritus—Docetaxel—pancreatic cancer	0.00125	0.0014	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA2—pancreatic cancer	0.00124	0.0109	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CD—pancreatic cancer	0.00123	0.0108	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Epirubicin—pancreatic cancer	0.00122	0.00138	CcSEcCtD
Methyl aminolevulinate—Oedema—Epirubicin—pancreatic cancer	0.00119	0.00134	CcSEcCtD
Methyl aminolevulinate—Infection—Epirubicin—pancreatic cancer	0.00118	0.00133	CcSEcCtD
Methyl aminolevulinate—Dizziness—Docetaxel—pancreatic cancer	0.00116	0.00131	CcSEcCtD
Methyl aminolevulinate—Discomfort—Doxorubicin—pancreatic cancer	0.00113	0.00128	CcSEcCtD
Methyl aminolevulinate—Rash—Docetaxel—pancreatic cancer	0.00111	0.00125	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Docetaxel—pancreatic cancer	0.00111	0.00125	CcSEcCtD
Methyl aminolevulinate—Headache—Docetaxel—pancreatic cancer	0.0011	0.00124	CcSEcCtD
Methyl aminolevulinate—Oedema—Doxorubicin—pancreatic cancer	0.0011	0.00124	CcSEcCtD
Methyl aminolevulinate—Infection—Doxorubicin—pancreatic cancer	0.00109	0.00123	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CB—pancreatic cancer	0.00107	0.00944	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Epirubicin—pancreatic cancer	0.00107	0.0012	CcSEcCtD
Methyl aminolevulinate—Nausea—Docetaxel—pancreatic cancer	0.00105	0.00118	CcSEcCtD
Methyl aminolevulinate—Fatigue—Epirubicin—pancreatic cancer	0.00102	0.00115	CcSEcCtD
Methyl aminolevulinate—Pain—Epirubicin—pancreatic cancer	0.00102	0.00115	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Doxorubicin—pancreatic cancer	0.000987	0.00111	CcSEcCtD
Methyl aminolevulinate—Fatigue—Doxorubicin—pancreatic cancer	0.000947	0.00107	CcSEcCtD
Methyl aminolevulinate—Urticaria—Epirubicin—pancreatic cancer	0.000943	0.00106	CcSEcCtD
Methyl aminolevulinate—Pain—Doxorubicin—pancreatic cancer	0.00094	0.00106	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2L1—pancreatic cancer	0.000891	0.00787	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TSC2—pancreatic cancer	0.000886	0.00782	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Epirubicin—pancreatic cancer	0.000875	0.000987	CcSEcCtD
Methyl aminolevulinate—Urticaria—Doxorubicin—pancreatic cancer	0.000873	0.000984	CcSEcCtD
Methyl aminolevulinate—Asthenia—Epirubicin—pancreatic cancer	0.000852	0.000961	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TSC2—pancreatic cancer	0.000851	0.00751	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Epirubicin—pancreatic cancer	0.00084	0.000948	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—STAT3—pancreatic cancer	0.000826	0.00729	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—NRAS—pancreatic cancer	0.000824	0.00728	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00081	0.000913	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—NFKBIA—pancreatic cancer	0.000808	0.00713	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD44—pancreatic cancer	0.000801	0.00707	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Doxorubicin—pancreatic cancer	0.000788	0.000889	CcSEcCtD
Methyl aminolevulinate—Dizziness—Epirubicin—pancreatic cancer	0.000785	0.000886	CcSEcCtD
Methyl aminolevulinate—Pruritus—Doxorubicin—pancreatic cancer	0.000777	0.000877	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NFKBIA—pancreatic cancer	0.000776	0.00685	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA1—pancreatic cancer	0.000775	0.00685	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGF—pancreatic cancer	0.000773	0.00683	CbGpPWpGaD
Methyl aminolevulinate—Rash—Epirubicin—pancreatic cancer	0.000749	0.000844	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Epirubicin—pancreatic cancer	0.000748	0.000844	CcSEcCtD
Methyl aminolevulinate—Headache—Epirubicin—pancreatic cancer	0.000744	0.000839	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGF—pancreatic cancer	0.000743	0.00656	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Doxorubicin—pancreatic cancer	0.000727	0.000819	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA2—pancreatic cancer	0.000722	0.00637	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—KRAS—pancreatic cancer	0.000709	0.00626	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Epirubicin—pancreatic cancer	0.000705	0.000795	CcSEcCtD
Methyl aminolevulinate—Rash—Doxorubicin—pancreatic cancer	0.000693	0.000781	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Doxorubicin—pancreatic cancer	0.000692	0.000781	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDH1—pancreatic cancer	0.000691	0.0061	CbGpPWpGaD
Methyl aminolevulinate—Headache—Doxorubicin—pancreatic cancer	0.000688	0.000776	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CD—pancreatic cancer	0.000688	0.00607	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CD—pancreatic cancer	0.00066	0.00583	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Doxorubicin—pancreatic cancer	0.000653	0.000736	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CA—pancreatic cancer	0.000652	0.00575	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HRAS—pancreatic cancer	0.000603	0.00532	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CB—pancreatic cancer	0.000599	0.00529	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CB—pancreatic cancer	0.000576	0.00508	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTNNB1—pancreatic cancer	0.000531	0.00469	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2L1—pancreatic cancer	0.000519	0.00458	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PTEN—pancreatic cancer	0.000518	0.00457	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TSC2—pancreatic cancer	0.000516	0.00455	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PTEN—pancreatic cancer	0.000497	0.00439	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—pancreatic cancer	0.00048	0.00424	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NFKBIA—pancreatic cancer	0.00047	0.00415	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—NRAS—pancreatic cancer	0.000462	0.00408	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—pancreatic cancer	0.000461	0.00407	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGF—pancreatic cancer	0.00045	0.00398	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NRAS—pancreatic cancer	0.000444	0.00392	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—pancreatic cancer	0.000421	0.00372	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDH1—pancreatic cancer	0.000419	0.0037	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—pancreatic cancer	0.000404	0.00357	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CD—pancreatic cancer	0.000401	0.00354	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KRAS—pancreatic cancer	0.000398	0.00351	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KRAS—pancreatic cancer	0.000382	0.00337	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CA—pancreatic cancer	0.000365	0.00323	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CA—pancreatic cancer	0.000351	0.0031	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CB—pancreatic cancer	0.000349	0.00308	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HRAS—pancreatic cancer	0.000338	0.00298	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HRAS—pancreatic cancer	0.000325	0.00287	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTNNB1—pancreatic cancer	0.00031	0.00273	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTEN—pancreatic cancer	0.000302	0.00266	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT1—pancreatic cancer	0.000299	0.00264	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT1—pancreatic cancer	0.000287	0.00253	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—pancreatic cancer	0.00028	0.00247	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—STAT3—pancreatic cancer	0.00027	0.00238	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NRAS—pancreatic cancer	0.000269	0.00238	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—pancreatic cancer	0.000245	0.00217	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KRAS—pancreatic cancer	0.000232	0.00205	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CA—pancreatic cancer	0.000213	0.00188	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HRAS—pancreatic cancer	0.000197	0.00174	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT1—pancreatic cancer	0.000174	0.00154	CbGpPWpGaD
